PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1528865
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1528865
Generic Oncology Drugs Market Size - By Drug Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy), Indication (Prostate, Lung, Breast), Route of Administration (Oral, Injectable), Distribution Channel & Global Forecast, 2024 - 2032
Generic Oncology Drugs Market size is projected to expand at 5.8% CAGR from 2024 to 2032, led by the rising prevalence of cancer, increasing demand for cost-effective treatment options, and the expiration of patents for key branded oncology drugs. According to data from the National Cancer Institute, in 2024, approximately 2,001,140 new cases of cancer will be diagnosed in the U.S. The launch of government initiatives and support for generic drug production is also accelerating the product appeal.
Significant advancements in pharmaceutical manufacturing and regulatory approvals are accelerating the availability of high-quality generic oncology drugs. The expansion of healthcare infrastructure in emerging economies is supporting the high demand for affordable cancer treatments. The growing awareness and acceptance of generics among healthcare providers and patients is driving the product uptake.
The overall market is segregated into drug type, indication, route of administration, distribution channel, and region.
Based on drug type, the industry value from the immunotherapy drugs segment is estimated to rise at a robust CAGR between 2024 and 2032, due to increasing cancer prevalence, advancements in immunotherapy research, and high demand for cost-effective treatments. The improving efficacy and fewer side effects compared to traditional therapies will boost the appeal of immunotherapies. The expiration of patents of key immunotherapy drugs, supportive government policies for generics, and growing awareness of immunotherapy benefits are also expanding the segment growth.
With regards to indication, the generic oncology drugs market from the lung cancer segment will gain significant traction by 2032. This is owing to the high prevalence of lung cancer, increasing demand for affordable treatment options, and advancements in generic drug formulations. The expiring patents of key lung cancer drugs will boost generic availability. The improving healthcare access in emerging markets, and the growing awareness of early diagnosis and treatment are further boosting the segment growth.
Regionally, the Europe generic oncology drugs market is estimated to grow at a substantial rate from 2024 to 2032, led by the high prevalence of cancer, rising demand for affordable treatments, and expiration of patents of major oncology drugs. The strong government support for generic drug production and presence of favorable reimbursement policies are accelerating drug deployment. The increasing healthcare expenditure, improving access to healthcare services, and the growing awareness of generic oncology drugs are fueling the regional market expansion.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing cancer prevalence
- 3.2.1.2 Patent expirations
- 3.2.1.3 Growing government support towards generics
- 3.2.1.4 Rising demand for personalized treatment
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Maintaining consistent quality standards
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Pipeline analysis
- 3.5 Regulatory landscape
- 3.6 Reimbursement scenario
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Chemotherapy drugs
- 5.3 Targeted therapy drugs
- 5.4 Immunotherapy drugs
- 5.5 Hormonal therapy drugs
- 5.6 Other drug types
Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Prostate cancer
- 6.3 Lung cancer
- 6.4 Breast cancer
- 6.5 Colorectal cancer
- 6.6 Leukemia
- 6.7 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 22021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Topical
- 7.4 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 202021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 The Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 AbbVie Inc.
- 10.2 Apotex Inc.
- 10.3 AstraZeneca
- 10.4 Biocon Ltd.
- 10.5 Gland Pharma Limited
- 10.6 Incyte Corporation
- 10.7 Lupin Pharmaceuticals, Inc.
- 10.8 Mylan N.V.
- 10.9 Natco Pharma Ltd.
- 10.10 Novartis Pharmaceuticals Corporation
- 10.11 Pfizer Inc.
- 10.12 Regeneron Pharmaceuticals Inc.
- 10.13 Synthon Pharmaceuticals, Inc.
- 10.14 Teva Pharmaceuticals
- 10.15 Zydus Lifesciences Limited
